Mannkind Corporation
A California biopharmaceutical company that makes Afrezza, an inhaled insulin for people with type 1 and type 2 diabetes. Instead of a needle, patients breathe a dry-powder insulin through a small inhaler, with the powder absorbed quickly through the lungs to manage mealtime blood sugar. Founder Alfred E. Mann, a serial inventor of medical devices, named the firm after himself and shaped it in the early 2000s by merging several of his companies. A fun quirk: Mann's dream was to free people with diabetes from daily injections — a needle-free ambition baked into the company's very name.
Granted 3.65M · Bought 29.5K · Sold 891.4K
Granted 1.24M · Bought 11.5K · Sold 254.0K
Granted 1.27M · Sold 338.7K
Granted 1.31M · Sold 469.0K
Granted 243.7K · Bought 38.7K · Sold 4.6K
Granted 200.0K
Granted 496.9K
Granted 538.6K · Sold 18.8K
Granted 393.2K
Granted 341.9K
Granted 227.6K
Granted 318.2K
Granted 100.0K · Bought 40.0K
Granted 35.0K
Bought 110.7K
Granted 107.0K
Granted 12.0K
Bought 27.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Castagna MichaelChief Executive Officer, Director · 67 transactions | +62.5% | 2.44M | 3.65M | 29.5K | 891.4K |
| Tross Stuart AChief People & Workpl Officer · 43 transactions | +65.4% | 1.03M | 1.24M | 11.5K | 254.0K |
| Thomson DavidEVP Genl Counsel & Secretary · 38 transactions | +49.4% | 826.3K | 1.27M | — | 338.7K |
| Binder Steven B.Director · 42 transactions | +51.5% | 808.0K | 1.31M | — | 469.0K |
| Galindo AlejandroEVP Endocrine Business Unit · 11 transactions | +44.4% | 777.1Kas of Aug 2022 | 243.7K | 38.7K | 4.6K |
| Kocinsky JosephChief Technology Officer · 4 transactions | +32.3% | 745.2Kas of Aug 2022 | 200.0K | — | — |
| Blank BurkhardEVP Chief Medical Officer · 6 transactions | — | 460.8Kas of Jul 2025 | 496.9K | — | — |
| Singh Sanjay REVP Technical Operations · 11 transactions | — | 455.2K | 538.6K | — | 18.8K |
| Sabella Lauren MEVP Operations · 11 transactions | — | 349.8Kas of Jul 2025 | 393.2K | — | — |
| Marasco DominicPres, Endocrine Business Unit · 4 transactions | — | 344.2K | 341.9K | — | — |
| Prentiss Christopher BChief Financial Officer · 5 transactions | — | 338.9K | 227.6K | — | — |
| Ahuja AjayChief Medical Officer · 1 transaction | — | 318.2K | 318.2K | — | — |
| Hooper Anthony CDirector · 4 transactions | +87.1% | 236.2K | 100.0K | 40.0K | — |
| Consiglio Ronald JDirector · 2 transactions | +30.5% | 132.3K | 35.0K | — | — |
| Grancio JenniferDirector · 1 transaction | +821.1% | 110.7K | — | 110.7K | — |
| Kay SabrinaDirector · 1 transaction | — | 107.0K | 107.0K | — | — |
| Shannon James SamuelDirector · 1 transaction | -67.9% | 36.5K | 12.0K | — | — |
| Mundkur ChristineDirector · 1 transaction | -15.1% | 27.7K | — | 27.7K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.72M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.